Shah logo.png
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
20 mai 2024 06h35 HE | Shah Capital
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder...
Shah logo.png
Shah Capital nominates two highly qualified independent director candidates for Novavax
15 avr. 2024 06h00 HE | Shah Capital
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price       Shah Capital which owns 6.7% of...
Final Logo-01.png
Vaccine Adjuvant Market is estimated to be US$ 2.0 billion by 2032; Rising Prevalence of Infectious Diseases to Fuel the Market Growth - By PMI
25 sept. 2023 14h00 HE | PMI
Covina, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Market overview: Adjuvant is formulated as a part of vaccine to induce protection against infection in human beings. Adjuvant has become an important...
FFF Enterprises Inc.
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
13 sept. 2023 13h34 HE | FFF
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Dyadic Logo Current.jpg
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
24 juil. 2023 08h30 HE | Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Dyadic Logo Current.jpg
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
10 août 2022 16h00 HE | Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic Logo Current.jpg
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
05 juil. 2022 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic Logo Current.jpg
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
09 mai 2022 08h30 HE | Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
10 janv. 2022 11h18 HE | The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snap, Novavax, Zillow, and Ginkgo Bioworks and Encourages Investors to Contact the Firm
04 janv. 2022 21h00 HE | Bragar Eagel & Squire
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...